Michel Meijer

Michel Meijer is an active neuroscience researcher contributing to UN Sustainable Development Goals through investigations of neurodegenerative and neuroinflammatory disorders. His work focuses on spinocerebellar ataxia, microglial biology, and multiple sclerosis, with 13 research outputs including peer-reviewed articles and datasets. He operates within collaborative academic networks across Dutch research institutions.

Meijer's research centers on molecular mechanisms of spinocerebellar ataxia type 23, where he examines mutant dynorphin A-induced Purkinje cell loss, and neuroimmunology, particularly microglial transcriptomes in multiple sclerosis and fetal development. His fingerprint analysis shows dominant activity in spinocerebellar ataxia (100%), microglia (88%), and Purkinje cell research (60%), utilizing genomics, molecular biology, and neuropathology to dissect disease pathways.

Analysis of his 2015-2022 publications reveals consistent focus on cerebellar disorders and neuroinflammation. The 2022 multiple sclerosis study demonstrates advanced transcriptomic profiling of macrophage heterogeneity, while his 2015 spinocerebellar ataxia work integrates genetic mutation analysis with functional outcomes. This trajectory highlights his interdisciplinary approach bridging neurogenetics, neuroimmunology, and clinical neurology.

Meijer collaborates extensively with Dutch neuroscience experts including N. Brouwer, B.J.L. Eggen, and S.M. Kooistra, indicating strong institutional ties to neurology and neuroimmunology research groups. His work contributes to understanding disease mechanisms in ataxia and multiple sclerosis through molecular and cellular investigations.